2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
-
- Liana Fraenkel
- Berkshire Medical Center, Pittsfield, Massachusetts, and Yale University School of Medicine New Haven Connecticut United States
-
- Joan M. Bathon
- Columbia University Irving Medical Center New York Presbyterian Hospital New York New York United States
-
- Bryant R. England
- University of Nebraska Medical Center and VA Nebraska–Western Iowa Health Care System Omaha Nebraska United States
-
- E. William St.Clair
- Duke University Medical Center Durham North Carolina United States
-
- Thurayya Arayssi
- Weill Cornell Medicine–Qatar Doha Qatar
-
- Kristine Carandang
- University of California San Diego
-
- Kevin D. Deane
- University of Colorado Aurora
-
- Mark Genovese
- Stanford University Medical Center Palo Alto California United States
-
- Kent Kwas Huston
- The Center for Rheumatic Disease/Allergy and Immunology Kansas City Missouri United States
-
- Gail Kerr
- Veterans Affairs Medical Center Georgetown and Howard University Washington DC United States
-
- Joel Kremer
- Albany Medical College and The Center for Rheumatology Albany New York United States
-
- Mary C. Nakamura
- University of California San Francisco
-
- Linda A. Russell
- Hospital for Special Surgery New York New York United States
-
- Jasvinder A. Singh
- University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center Birmingham Alabama United States
-
- Benjamin J. Smith
- Florida State University College of Medicine School of Physician Assistant Practice Tallahassee
-
- Jeffrey A. Sparks
- Brigham and Women’s Hospital and Harvard Medical School Boston Massachusetts United States
-
- Shilpa Venkatachalam
- Global Healthy Living Foundation Upper Nyack New York United States
-
- Michael E. Weinblatt
- Brigham and Women’s Hospital and Harvard Medical School Boston Massachusetts United States
-
- Mounir Al‐Gibbawi
- American University of Beirut Beirut Lebanon
-
- Joshua F. Baker
- Corporal Michael J. Crescenz VA Medical Center and the University of Pennsylvania Philadelphia Pennsylvania United States
-
- Kamil E. Barbour
- Centers for Disease Control and Prevention Atlanta Georgia United States
-
- Jennifer L. Barton
- Oregon Health & Science University and VA Portland Health Care System Portland Oregon United States
-
- Laura Cappelli
- Johns Hopkins Medicine Baltimore Maryland United States
-
- Fatimah Chamseddine
- American University of Beirut Beirut Lebanon
-
- Michael George
- University of Pennsylvania Philadelphia
-
- Sindhu R. Johnson
- Toronto Western Hospital Mount Sinai Hospital Institute of Health Policy Management and Evaluation University of Toronto Toronto Ontario Canada
-
- Lara Kahale
- American University of Beirut Beirut Lebanon
-
- Basil S. Karam
- American University of Beirut Beirut Lebanon
-
- Assem M. Khamis
- American University of Beirut Beirut Lebanon
-
- Iris Navarro-Millán
- Weill Cornell Medicine New York New York United States
-
- Reza Mirza
- University of Toronto Toronto Ontario Canada
-
- Pascale Schwab
- Oregon Health & Science University and VA Portland Health Care System Portland Oregon United States
-
- Namrata Singh
- University of Washington Seattle
-
- Marat Turgunbaev
- American College of Rheumatology Atlanta Georgia United States
-
- Amy S. Turner
- American College of Rheumatology Atlanta Georgia United States
-
- Sally Yaacoub
- American University of Beirut Beirut Lebanon
-
- Elie A. Akl
- American University of Beirut Beirut Lebanon
抄録
<jats:sec><jats:title>Objective</jats:title><jats:p>To develop updated guidelines for the pharmacologic management of rheumatoid arthritis.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the certainty of evidence. A voting panel comprising clinicians and patients achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The guideline addresses treatment with disease‐modifying antirheumatic drugs (DMARDs), including conventional synthetic DMARDs, biologic DMARDs, and targeted synthetic DMARDs, use of glucocorticoids, and use of DMARDs in certain high‐risk populations (i.e., those with liver disease, heart failure, lymphoproliferative disorders, previous serious infections, and nontuberculous mycobacterial lung disease). The guideline includes 44 recommendations (7 strong and 37 conditional).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>This clinical practice guideline is intended to serve as a tool to support clinician and patient decision‐making. Recommendations are not prescriptive, and individual treatment decisions should be made through a shared decision‐making process based on patients’ values, goals, preferences, and comorbidities.</jats:p></jats:sec>
収録刊行物
-
- Arthritis & Rheumatology
-
Arthritis & Rheumatology 73 (7), 1108-1123, 2021-06-08
Wiley